Abstract 407P
Background
About 18% of patients (pts) with advanced NSCLC have alterations in the Stk11/LKB1 pathway, resulting in an aggressive phenotype with short survival and poor response to standard therapies.
Methods
We analyzed 187 NSCLC pts at Istituto Nazionale dei Tumori in Milan with LKB1-inactive, defined as absence in IHC expression (exp) or Stk11 mutations (mut) detected by NGS. Progression-free survival (PFS) was calculated from the start of first line treatment and overall survival (OS) from metastatic diagnosis; Kaplan-Meier and COX models were used to assess PFS and OS differences.
Results
Median(m) age was 68.3 years, 69% were male, 84.5% had adenocarcinoma, ECOG PS was ≥ 2 in 16.7%. PD-L1 TPS was
Conclusions
We analyzed clinicopathological features and treatment response in a large real-world cohort of LKB1-inactive NSCLC pts. Loss of LKB1 exp appears to be more relevant than Stk11 mut, suggesting the occurrence of epigenetic mechanisms. Additionally, the percentage of patients who never started treatment, confirms the strong negative prognostic role of this biomarker.
Funding
Has not received any funding.
Disclosure
M. Occhipinti: Financial Interests, Personal, Other, Honoraria, consulting and advisory role: AstraZeneca, BMS, MSD; Financial Interests, Personal, Other, travel, accomodation and expenses: Lilly. M. Brambilla: Financial Interests, Personal, Other, Travel grant: Lilly. C. Proto: Financial Interests, Personal, Other, fees for travel, accomodation and expenses; research funding and consulting or advisory fees: AstraZeneca, Roche, MSD; Financial Interests, Personal, Other, research funding and consulting or advisory fees: BMS; Financial Interests, Personal, Other, consulting or advisory fees: Janssen; Financial Interests, Personal, Other, research funding: Pfizer, Celgene, Daiichi Sankyo. A. Prelaj: Financial Interests, Personal, Other, Training of personnel: AstraZeneca, Italfarma; Financial Interests, Personal, Invited Speaker, The Hive Project: Discussant: Roche; Financial Interests, Personal, Advisory Board, Advisory board in Lung Cancer project: BMS; Financial Interests, Personal, Other, Travel Grant: Janssen; Financial Interests, Personal, Advisory Board: Janssen, AstraZeneca; Financial Interests, Personal, Invited Speaker: Medsir, Novartis, Lilly; Financial Interests, Institutional, Invited Speaker: Bayer, BMS, AstraZeneca, Lilly, MSD, Spectrum, Roche. L. Mazzeo: Financial Interests, Personal, Other, Honoraria: Novartis; Financial Interests, Personal, Other, Conference Grants: Daiichi Sankyo, Leo Pharma, Sanofi. T. Beninato: Financial Interests, Personal, Other, Honoraria, Travel accomodation and conference grants: MSD; Financial Interests, Personal, Other, Travel accomodation and conference grants: Sanofi, Pfizer, Lilly. D. Signorelli: Financial Interests, Personal, Other, fees: AstraZeneca, Roche, BMS, MSD, Sanofi, Boehringer Ingelheim, Novartis; Financial Interests, Institutional, Other, fees: Lilly, Pfizer. M.C. Garassino: Financial Interests, Personal, Advisory Board: Eli Lilly, SeaGen International GmbH, Eli Lilly, Incyte, GSK, Bayer Healthcare Pharmaceuticals, Blueprint Medicines, AstraZeneca and Daiichi Sankyo Oncology Teams, Roche, Daiichi Sankyo, Mirati Therapeutics, Inc, Daiichi Sankyo/AstraZeneca, AstraZeneca Poland, Daiichi Sankyo, Inc., MSD, Eli Lilly, Pfizer, Astrazeneca/MedImmune, Sanofi Genzyme corporation, Sanofi/Prex, Regeneron Pharmaceuticals, Eli Lilly, Mirati Therapeutics, Inc., Janssen Pharmaceutical, Io Biotech, Merck, Novocure, Nuvation, Pfizer, Revolution Medicine, Roche, Merck, AstraZeneca, Bayer, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Gilead, Mirati; Financial Interests, Personal, Invited Speaker: WebMD, WebMD Oncology/Takeda, MSD Italia, Srl, Grupo Pacifico-Secretaria Técnica ICAPEM/AstraZeneca, S. O.S S.r.l, Medscape, ecancer, Ideology, Gilead, Daiichi Sankyo; Financial Interests, Personal, Invited Speaker, Global Experts Meeting: AstraZeneca; Financial Interests, Personal, Other, AstraZeneca Spain: Invitation to a lung cancer investigator meeting: AstraZeneca; Financial Interests, Personal, Advisory Board, Advisory Boards: Takeda, Daiichi Sankyo, BeiGene; Financial Interests, Personal, Other, PACIFIC-R Global Scientific Committee: AstraZeneca; Financial Interests, Personal, Other, Steering Committee member and Co-chair at the AstraZeneca Lung Cancer Summit 2019: AstraZeneca; Financial Interests, Personal, Other, MK-3475 KN671 Steering Committee.: MSD; Financial Interests, Personal, Other, Pacific 6 International Coordinating Investigator: AstraZeneca; Financial Interests, Personal, Other, Janssen Scientific Advisory Board and Therapeutic Area Steering Committee Meeting on Lung Cancer: Janssen; Financial Interests, Personal, Expert Testimony: AstraZeneca UK; Financial Interests, Personal, Other, Pfizer Global Lung Cancer Educational Programme - Steering Committee: Pfizer; Financial Interests, Personal, Other, Seattle Genetics Lung Cancer Platform Study: Seattle Genetics; Financial Interests, Personal, Other, GSK Lung Cancer Global Council: GSK; Financial Interests, Personal, Other, PACIFIC-R Scientific Committee: AstraZeneca UK; Financial Interests, Personal, Other, GSK-Garassino-ZEAL Steering Committee 2020–23: GSK; Financial Interests, Personal, Advisory Board, Advisory Board: AbbVie, Abion, Bayer; Financial Interests, Personal, Advisory Board, Advisory boards: Merck, Sanofi, Gilead; Financial Interests, Personal, Invited Speaker, Satellite Symposium: Merck; Financial Interests, Personal, Invited Speaker, Invited speaker: Medscape; Financial Interests, Personal, Advisory Board, Invited speaker: OncoHost; Financial Interests, Personal, Advisory Board, Advisor: Boehringer Ingelheim; Financial Interests, Personal, Invited Speaker, Member of the MK-3475 KN671 Steering Committee (KEYNOTE-671): MSD; Financial Interests, Personal, Invited Speaker, Coordinating investigator for the MK-3475 KEYNOTE 189: MSD; Financial Interests, Personal and Institutional, Invited Speaker, Pacific 6 Steering Committee and International Coordinating Investigator: AstraZeneca; Financial Interests, Institutional, Invited Speaker, Steering Committee ML41118 Roche: Roche; Financial Interests, Institutional, Invited Speaker, TURNING POINT: Bayer; Financial Interests, Institutional, Invited Speaker, A Phase 1: Janssen; Financial Interests, Institutional, Invited Speaker, Array 818-202: Pfizer; Financial Interests, Institutional, Invited Speaker, PAPILLON Study: Janssen; Financial Interests, Institutional, Invited Speaker, Phase II: Celgene Corporation, Spectrum Pharmaceuticals, Merck Serono; Financial Interests, Institutional, Invited Speaker: Amgen; Financial Interests, Institutional, Invited Speaker, Phase 3: Bluprint; Financial Interests, Institutional, Invited Speaker, Phase III: Amgen, GSK Research & Develpoment Ltd., Novartis; Financial Interests, Institutional, Invited Speaker, Phase III - CEACAM5: Sanofi; Financial Interests, Institutional, Invited Speaker, Phase I-JNJ-61186372, a Human Bispecific EGFR and cMet Antibody: Janssen; Financial Interests, Institutional, Invited Speaker, Phase 3 Study RESILIENT: Ipsen Bioscience Inc.; Financial Interests, Institutional, Invited Speaker, Phase II - SAVANNAH: AstraZeneca S.p.A.; Financial Interests, Institutional, Invited Speaker, phase III NEOCOAST: MedImmune LCC; Financial Interests, Institutional, Invited Speaker, Phase II - coast: MedImmune LCC; Financial Interests, Institutional, Invited Speaker, Phase III - ADRIATIC: AstraZeneca; Financial Interests, Institutional, Invited Speaker, Phase III (CANOPY-1): Novartis; Financial Interests, Institutional, Invited Speaker, Phase 1b: Exelixis Inc.; Financial Interests, Institutional, Invited Speaker, Phase 3-GO40241: Roche; Financial Interests, Institutional, Invited Speaker, Phase IIICASPIAN: AstraZeneca; Financial Interests, Institutional, Invited Speaker, MK3475-091 - PEARLS: Merck; Financial Interests, Institutional, Invited Speaker, Phase III - Roche GO29431: Roche; Financial Interests, Institutional, Invited Speaker, Phase III CA209-017: BMS; Financial Interests, Institutional, Invited Speaker, Phase III - ARCTIC: AstraZeneca; Financial Interests, Institutional, Invited Speaker, Phase III - AURA 3: AstraZeneca AB; Financial Interests, Institutional, Invited Speaker, Phase III CA209-057: BMS; Financial Interests, Institutional, Invited Speaker, OPEL/2014/14/067: Otsuka Pharmaceutical Italy S.r.l.; Financial Interests, Institutional, Invited Speaker, Phase II - VISION: Merck KGaA; Financial Interests, Institutional, Invited Speaker, Phase III MK-3475-715: Incyte Corporation; Financial Interests, Institutional, Invited Speaker, Phase 1/2 (TRIDENT-1): Turning Point Therapeutics, Inc.; Financial Interests, Institutional, Invited Speaker, HERTHENA-Lung01: A Phase 2: Daiichi Sankyo Development Ltd.; Financial Interests, Institutional, Invited Speaker, Phase II ATLANTIC: AstraZeneca S.p.A.; Financial Interests, Institutional, Invited Speaker, Clinical trial: Affimed; Financial Interests, Institutional, Invited Speaker, Clinical trial poziotinib: spectrum; Non-Financial Interests, Personal, Principal Investigator, STYLE Trial: Pfizer; Non-Financial Interests, Personal, Principal Investigator, Studio TYME: Eli Lilly; Non-Financial Interests, Personal, Principal Investigator, People: MSD; Non-Financial Interests, Personal, Principal Investigator, FAME trial: Istituto Nazionale dei Tumori; Non-Financial Interests, Personal, Principal Investigator, POST-ALK: Istituto Nazionale dei Tumori; Non-Financial Interests, Personal, Principal Investigator, Bando finalizzata Mesotelioma: Istituto Nazionale dei Tumori; Non-Financial Interests, Personal, Principal Investigator, TERAVOLT: Istituto Nazionale dei Tumori; Non-Financial Interests, Personal, Principal Investigator, Progetto Timoma: Istituto Nazionale dei Tumori; Non-Financial Interests, Personal, Principal Investigator, APOLLO: Istituto Nazionale dei Tumori; Non-Financial Interests, Personal, Principal Investigator, Beverly: Istituto dei Tumori Pascale - Napoli; Non-Financial Interests, Personal, Principal Investigator, IND227: Istituto dei Tumori Pascale - Napoli; Non-Financial Interests, Personal, Principal Investigator, RAMES: GOIRC; Non-Financial Interests, Personal, Principal Investigator, Studio CHANCE: GOIRC; Non-Financial Interests, Personal, Principal Investigator, Creta trial: Sant’Orsola Malpighi - Bologna (Alma Mater Studiorum Università Bologna); Non-Financial Interests, Personal, Principal Investigator, MILES 5: Istituto dei Tumori Pascale - Napoli; Non-Financial Interests, Personal, Principal Investigator, LIPI: Gustave Roussy Parigi Lipi Trial- no profit; Non-Financial Interests, Personal, Principal Investigator: AO Spedali Civili Brescia; Non-Financial Interests, Personal, Principal Investigator, phase III trial: European Thoracic Oncology Platform (ETOP); Non-Financial Interests, Personal, Leadership Role, Honorary President and Founder: Women for Oncology Italy; Non-Financial Interests, Personal, Other, Member of ASCO Scientific Committee (2018–2021): ASCO; Non-Financial Interests, Personal, Leadership Role, Board member: AIOT (Associazione Italiana Oncologia Toracica); Non-Financial Interests, Personal, Member: AIOM, AIOT; Non-Financial Interests, Personal, Member, WCLC annual congress Lung Cancer Track: WCLC; Non-Financial Interests, Personal, Member, Scientific Committee: IPOP (Italian lung cancer charity), TUTOR (Italian thymic malignancies charity); Non-Financial Interests, Personal, Member, Member since 2013–2018: EMA Scientific Advisory Group (SAG); Non-Financial Interests, Personal, Other, Scientific Programme Committee: AACR; Non-Financial Interests, Personal, Leadership Role, previous ESMO National Societies Committee Chair and ESMO Council Member: ESMO; Other, Personal, Other, Travel, Accommodations, Expenses: Pfizer; Other, Personal, Other, Relationships to Disclose Travel, Accommodations, Expenses: Roche, AstraZeneca; Other, Personal, Other, travel and accomodation: Merck. F.G.M. De Braud: Financial Interests, Personal, Other, research grant/funding, consulting fees/advisory board, IQVIA Speaker Bureau: Roche; Financial Interests, Personal, Other, consulting fees/advisory board: EMD Serono, NMS Nerviano Medical Science, MSD, sanofi, menarini, AstraZeneca, Pierre Fabre, Mattioli 1885, MCCann Health, Taiho; Financial Interests, Personal, Other, research grant/funding, consulting fees/advisory board: BMS; Financial Interests, Personal, Other, research grant/funding, consulting fees/advisory board: Novartis; Financial Interests, Personal, Other, consulting fees/advisory board: Incyte; Financial Interests, Personal, Other, research grant/funding: Merck Sharp & Dohme Spa, Daiichi Sankyo, Basilea Pharmaceutica International, Janssen-Cilag International NV, Merck KGAA. G. Lo Russo: Financial Interests, Personal, Advisory Board: MSD, Novartis, AstraZeneca, BMS, Sanofi, Pfizer, Roche, Lilly, GSK, Daiichi Sankyo, Johnson And Johnson, Regeneron, Merck, Pierre Fabre; Financial Interests, Personal, Invited Speaker: Italfarmaco, Merck, BMS, Lilly, Sanofi; Financial Interests, Institutional, Other, Contribute For Meeting Organization: Janssen; Financial Interests, Institutional, Other, Contribute For Meeting Organization: Bayer; Financial Interests, Personal, Other, Travel Accommodation: Amgen, MSD; Financial Interests, Institutional, Other, Contribute to meeting organization: BeiGene; Financial Interests, Institutional, Invited Speaker: MSD, BMS, Roche, GSK, Celgene, Novartis, AstraZeneca, Amgen, Lilly. All other authors have declared no conflicts of interest.